Probity Advisors Inc. acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 2,371 shares of the company's stock, valued at approximately $252,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in BioNTech by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company's stock valued at $227,000 after purchasing an additional 209 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in BioNTech by 7.1% in the 1st quarter. SBI Securities Co. Ltd. now owns 3,673 shares of the company's stock valued at $334,000 after purchasing an additional 244 shares during the last quarter. LRI Investments LLC lifted its stake in BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after purchasing an additional 312 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in BioNTech in the 1st quarter valued at approximately $36,000. Finally, GF Fund Management CO. LTD. lifted its stake in BioNTech by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock valued at $229,000 after purchasing an additional 453 shares during the last quarter. Institutional investors own 15.52% of the company's stock.
BioNTech Trading Down 1.0%
BNTX opened at $106.89 on Wednesday. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $129.27. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $103.65 and a 200-day moving average of $104.19. The stock has a market cap of $25.70 billion, a PE ratio of -66.81 and a beta of 1.45.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The firm had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same quarter last year, the company earned ($3.36) earnings per share. The company's quarterly revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on BNTX. JPMorgan Chase & Co. upped their price target on shares of BioNTech from $116.00 to $121.00 and gave the company a "neutral" rating in a research report on Monday, September 22nd. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. HC Wainwright restated a "buy" rating and issued a $136.00 price target on shares of BioNTech in a research report on Monday, September 8th. Morgan Stanley decreased their price target on shares of BioNTech from $133.00 to $131.00 and set an "overweight" rating for the company in a research report on Friday, October 10th. Finally, Bank of America upped their price target on shares of BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Ten investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and an average target price of $134.32.
View Our Latest Analysis on BNTX
BioNTech Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
